Last reviewed · How we verify
ST266
At a glance
| Generic name | ST266 |
|---|---|
| Sponsor | Noveome Biotherapeutics, formerly Stemnion |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (PHASE1, PHASE2)
- Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis (PHASE2)
- ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects (PHASE2)
- Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects (PHASE1)
- Safety and Tolerability Study of IV ST266 in COVID-19 Subjects (PHASE1)
- ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects (PHASE2)
- Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis (PHASE2)
- Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ST266 CI brief — competitive landscape report
- ST266 updates RSS · CI watch RSS
- Noveome Biotherapeutics, formerly Stemnion portfolio CI